-
-
Login
Dexcom has agreed to acquire Nutrisense, bringing nutrition coaching and metabolic health services into its growing ecosystem. The deal offers the clearest sign yet that the future of CGM could extend far beyond traditional diabetes management.
Dexcom has warned that some G7 sensors intended for destruction after failing company quality standards were allegedly stolen and resold through unofficial supply channels, triggering concern across diabetes forums about counterfeit and diverted CGM devices entering circulation.
Dexcom’s Investor Day gave the clearest public preview yet of G8 CGM. From launch timing and 15-day wear to a smaller sensor and future ketone sensing, here’s what users need to know.
An update on Dexcom's 2026 plans with changes in senior leadership and a push for wider access to CGM technology.
We reflect on Dexcom's performance in 2025 and get up-to-date with news of their plans for a G8 sensor and international expansion.
News that approval from the FDA of the Dexcom G7 15 day CGM in the US, with a grace period of 12 hours, makes this the longest lasting CGM.
Dexcom's financial filings reveal a warning letter from the FDA regarding processing in 2 of its manufacturing plants.
News that Abbott and Dexcom have agreed not to sue each other for patents relating to their CGM tech for another 10 years.
